Diamedica Stock Today

DMAC -  USA Stock  

USD 3.53  0.08  2.32%

Diamedica Therapeutics is trading at 3.53 as of the 2nd of August 2021, a 2.32 percent increase since the beginning of the trading day. The stock's open price was 3.45. Diamedica Therapeutics has 51 percent odds of going through some form of financial distress in the next two years and has generated negative returns to investors over the last 90 days. Equity ratings for Diamedica Therapeutics are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 3rd of July 2021 and ending today, the 2nd of August 2021. Click here to learn more.
 Market Performance
0 of 100
  Odds Of Distress
Over 51

Diamedica Therapeutics Stock Profile

The upcoming quarterly report is expected on the 10th of August 2021. DiaMedica Therapeutics Inc., a clinical stage biopharmaceutical company, develops treatments for neurological and kidney diseases. DiaMedica Therapeutics Inc. was incorporated in 2000 and is headquartered in Minneapolis, Minnesota. Diamedica Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 10 people. more on Diamedica Therapeutics
Diamedica Therapeutics generates negative expected return over the last 90 days
Diamedica Therapeutics has high historical volatility and very poor performance
Diamedica Therapeutics has high likelihood to experience some financial distress in the next 2 years
The company reported the previous year's revenue of 447.37 K. Net Loss for the year was (12.29 M) with profit before overhead, payroll, taxes, and interest of 500 K.
Diamedica Therapeutics currently holds about 27.51 M in cash with (9.19 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.47.
Diamedica Therapeutics has a frail financial position based on the latest SEC disclosures
Latest headline from www.equities.com: DiaMedica falls 4.70 percent to Close at 3.45 on July 30 - Equities.com
Diamedica Therapeutics Fama & French Pharmaceutical Products
Pharmaceutical Products
Fama & French Classification
Diamedica Therapeutics SEC Filings
Diamedica Therapeutics SEC Filings Security & Exchange Commission EDGAR Reports
Legal NameDiamedica Therapeutics
President CEO, DirectorRick Pauls  (View All)
Thematic Classification
Currently Active Investing Idea (view all)
  Pharmaceutical Products
Average Analyst Recommendation
Analysts covering Diamedica Therapeutics report their recommendations after researching Diamedica Therapeutics' financial statements, talking to executives and customers, or listening in on Diamedica Therapeutics' conference calls. The current trade recommendation is based on an ongoing consensus estimate among financial analysts covering Diamedica Therapeutics. The Diamedica consensus assessment is calculated by taking the average forecast from all of the analysts covering Diamedica Therapeutics.
Strong Buy4 Opinions
Piotroski F Score
Piotroski F-Score is a popular financial indicator that puts together nine criteria to evaluate the financial strength of Diamedica Therapeutics based on its profitability, leverage, liquidity, source of funds, and operating efficiency. it is an academic score (developed by Joseph Piotroski in 2002) to determine the current strength of Diamedica Therapeutics financial position. Scores of 8 and 9 are usually classified as strong value stocks, whereas scores of 2 or below are considered weak value stocks.
 2 - FrailDetails
Current ValueLast YearChange From Last Year 10 Year Trend
Weighted Average Shares13.6 M15.7 M
Fairly Down
Increasing
Slightly volatile
Weighted Average Shares Diluted13.6 M15.7 M
Fairly Down
Increasing
Slightly volatile
Total Assets30.3 M28.1 M
Significantly Up
Increasing
Slightly volatile
Total Liabilities1.9 M2.1 M
Moderately Down
Increasing
Slightly volatile
Current Assets30.1 M27.9 M
Significantly Up
Increasing
Slightly volatile
Current Liabilities1.8 MM
Fairly Down
Increasing
Slightly volatile
Total Debt123.7 K118 K
Sufficiently Up
Increasing
Slightly volatile
Gross Margin0.890.9
Fairly Down
Decreasing
Slightly volatile
Asset Turnover0.04470.045
Slightly Down
Decreasing
Slightly volatile
Macroaxis Advice
Unlike general analyst consensus, Macroaxis buy hold or sell recommendation is provided in the context of your current investment horizon and risk tolerance. The advice algorithm takes into account all of Diamedica Therapeutics' available fundamental, technical, and predictive indicators. Your current horizon is 90 days - details
Cautious HoldUndervalued
Financial Strength
Diamedica Therapeutics' financial strength is of vital concern to both outside investors and internal stakeholders. Efficiency and cost control are keys to Diamedica Therapeutics' success, along with its ability to generate sufficient cash flow to pay bills, repay debt, and make a consistent year-to-year profit.
Financial leverage usually refers to the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Diamedica Therapeutics' financial leverage. It provides some insight into what part of Diamedica Therapeutics' total assets is financed by creditors.
Share Download
Share Download
By using current balance sheet information, investors can analyze the liability, assets, and equity on Diamedica Therapeutics' books and decide whether to invest or hold. Statistics such as return on equity (ROE), debt to equity (D/E) help investors determine how Diamedica Therapeutics deploys its capital and how much of that capital is borrowed.
Liquidity
Diamedica Therapeutics cash flow analysis is essential to understand how it generates and spends money over a specific period. It can also help you figure out where your money is going and how much cash you have available at a given moment. The company currently holds 118 K in liabilities with Debt to Equity (D/E) ratio of 0.0, which may suggest the company is not taking enough advantage from borrowing. Diamedica Therapeutics has a current ratio of 13.49, suggesting that it is liquid enough and is able to pay its financial obligations when due.

Operating Cash Flow

(9.91 Million)Share
Diamedica Therapeutics (DMAC) is traded on NASDAQ Exchange in USA. It is located in Two Carlson Parkway and employs 10 people. Diamedica Therapeutics is listed under Pharmaceutical Products category by Fama And French industry classification. The company currently falls under 'Micro-Cap' category with current market capitalization of 65.19 M. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Diamedica Therapeutics's market, we take the total number of its shares issued and multiply it by Diamedica Therapeutics's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and these looking for more risk prefer small-cap and mid-cap equities. Diamedica Therapeutics conducts business under Healthcare sector and is part of Biotechnology industry. The entity has 18.79 M outstanding shares of which 186.97 K shares are currently shorted by private and institutional investors with about 1.92 trading days to cover. Diamedica Therapeutics currently holds about 27.51 M in cash with (9.19 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.47.
Check Diamedica Therapeutics Probability Of Bankruptcy
Ownership
Diamedica Therapeutics holds a total of eighteen million seven hundred ninety thousand outstanding shares. 30% of Diamedica Therapeutics outstanding shares are owned by other corporate entities. Institutional investors are typically referred to investors that purchase positions in a given stock to benefit from reduced commissions. Consequently, institutional investors are subject to different rules and regulation than regular investors. Please look out for any change in current institutional holding as this could mean something significant has changed at the company or about to change. Please note that no matter how much assets the company secures, if the real value of the firm is less than the current market value, you may not be able to make money on it.

Ownership Allocation (%)

Check Diamedica Ownership Details

Diamedica Stock Price Odds Analysis

What are Diamedica Therapeutics' target price odds to finish over the current price? Depending on a normal probability distribution, the odds of Diamedica Therapeutics jumping above the current price in 90 days from now is about 91.94%. The Diamedica Therapeutics probability density function shows the probability of Diamedica Therapeutics stock to fall within a particular range of prices over 90 days. Given the investment horizon of 90 days Diamedica Therapeutics has a beta of 0.1265 suggesting as returns on the market go up, Diamedica Therapeutics average returns are expected to increase less than the benchmark. However, during the bear market, the loss on holding Diamedica Therapeutics will be expected to be much smaller as well. Additionally, the company has a negative alpha, implying that the risk taken by holding this instrument is not justified. Diamedica Therapeutics is significantly underperforming DOW.
 Odds Down 3.53HorizonTargetOdds Up 3.53 
8.03%90 days
 3.53 
91.94%
Based on a normal probability distribution, the odds of Diamedica Therapeutics to move above the current price in 90 days from now is about 91.94 (This Diamedica Therapeutics probability density function shows the probability of Diamedica Stock to fall within a particular range of prices over 90 days) .

Diamedica Therapeutics Historical Income Statement

Diamedica Therapeutics Income Statement is one of the three primary financial statements used for reporting Diamedica's overall financial performance over a current year or for a given accounting period. An Income Statement sometimes referred to as the statement of Diamedica Therapeutics revenue and expense. Diamedica Therapeutics Income Statement primarily focuses on the company's revenues and expenses during a particular period.
As of August 2, 2021, Consolidated Income is expected to decline to about (12.6 M). In addition to that, Earning Before Interest and Taxes EBIT is expected to decline to about (12.6 M) View More Fundamentals

Diamedica Stock Against Markets

Picking the right benchmark for Diamedica Therapeutics stock is fundamental to making educated investment choices. Many naive investors compare their positions with the S&P 500 or with the Nasdaq. But these benchmarks are not all-inclusive and generally should be used only for large-capitalization equities or stock offerings from large companies. When the price of a selected benchmark declines in a down market, there may be an uptick in Diamedica Therapeutics stock price where buyers come in believing the asset is cheap. The opposite is true when the market is bullish; so, accurately picking the benchmark for Diamedica Therapeutics is critical whether you are bullish or bearish towards Diamedica Therapeutics at a given time.

Be your own money manager

Our tools can tell you how much better you can do entering a position in Diamedica Therapeutics without increasing your portfolio risk or giving up expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate.risk-adjusted returns of your individual positions relative to your overall portfolio.

Did you try this?

Run Portfolio Rebalancing Now

   

Portfolio Rebalancing

Analyze risk-adjusted returns against different time horizons to find asset-allocation targets
All  Next Launch Module

Diamedica Therapeutics Corporate Directors

Diamedica Therapeutics corporate directors refer to members of a Diamedica Therapeutics board of directors. The board of directors generally takes responsibility for the Diamedica Therapeutics' affairs and long-term direction of the entity. A corporate director does not make decisions for the corporation on his own. As a member of the board of directors, she or he must function as a part of a group that makes decisions on behalf of the business only by the board of directors' meetings. To pass a resolution, a majority of Diamedica Therapeutics' board members must vote for the resolution. The Diamedica Therapeutics board of directors' duties also include the election, removal, and supervision of officers, including the adoption, amendment, and repeal of bylaws.
Michael Giuffre - Independent DirectorProfile
James Parsons - DirectorProfile
Jerry Xiao - DirectorProfile
Harry Alcorn - DirectorProfile
Continue to Investing Opportunities. Note that the Diamedica Therapeutics information on this page should be used as a complementary analysis to other Diamedica Therapeutics' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Bond Directory module to find actively traded corporate debentures issued by US companies.

Complementary Tools for Diamedica Stock analysis

When running Diamedica Therapeutics price analysis, check to measure Diamedica Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Diamedica Therapeutics is operating at the current time. Most of Diamedica Therapeutics' value examination focuses on studying past and present price action to predict the probability of Diamedica Therapeutics' future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Diamedica Therapeutics' price. Additionally, you may evaluate how the addition of Diamedica Therapeutics to your portfolios can decrease your overall portfolio volatility.
ETF Directory
Find actively traded Exchange Traded Funds (ETF) from around the world
Go
Cryptocurrency Center
Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency
Go
Positions Ratings
Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance
Go
Equity Analysis
Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities
Go
Bollinger Bands
Use Bollinger Bands indicator to analyze target price for a given investing horizon
Go
Price Ceiling Movement
Calculate and plot Price Ceiling Movement for different equity instruments
Go
Financial Widgets
Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets
Go
Sync Your Broker
Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors.
Go
Portfolio Suggestion
Get suggestions outside of your existing asset allocation including your own model portfolios
Go
The market value of Diamedica Therapeutics is measured differently than its book value, which is the value of Diamedica that is recorded on the company's balance sheet. Investors also form their own opinion of Diamedica Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Diamedica Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Diamedica Therapeutics' market value can be influenced by many factors that don't directly affect Diamedica Therapeutics underlying business (such as pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Diamedica Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine Diamedica Therapeutics value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Diamedica Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.